Drugs / w1.6W
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01410825 | Jul 2011 → Sep 2024 | Wiskott-Aldrich syndrome | David Williams | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | w1.6W | “This w1.6\_hWASP\_WPRE (VSVg) LV (abbreviated as w1.6W) has been shown to be efficacious in both in vitro and in vivo preclinical models.” NCT01410825 ↗ |
| Known as | w1.6\_hWASP\_WPRE (VSVg) LV | “This w1.6\_hWASP\_WPRE (VSVg) LV (abbreviated as w1.6W) has been shown to be efficacious in both in vitro and in vivo preclinical models.” NCT01410825 ↗ |